Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report

Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report

BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limi...

Full description

Bibliographic Details
Main Authors: Dominik Lehrieder, Nikolaos Zapantis, Mirko Pham, Michael Klaus Schuhmann, Axel Haarmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Neurology
Subjects:
NMOSD
inebilizumab
AQP4
longitudinally extensive transverse myelitis
optic neuritis
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1297341/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1297341/full

Similar Items